Adam R. Craig - 24 Jan 2023 Form 4 Insider Report for CTI BIOPHARMA CORP

Role
President and CEO, Director
Signature
Adam R. Craig
Issuer symbol
N/A
Transactions as of
24 Jan 2023
Net transactions value
-$440,163
Form type
4
Filing time
26 Jan 2023, 16:17:19 UTC
Previous filing
03 Jan 2023
Next filing
16 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTIC common stock Options Exercise $69,980 +83,200 +283% $0.8411* 112,640 24 Jan 2023 Direct
transaction CTIC common stock Sale $499,200 -83,200 -74% $6.00 29,440 24 Jan 2023 Direct F1
transaction CTIC common stock Options Exercise $1,781 +2,117 +7.2% $0.8411* 31,557 24 Jan 2023 Direct
transaction CTIC common stock Sale $12,723 -2,117 -6.7% $6.01 29,440 24 Jan 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -83,200 -15% $0.000000 472,171 24 Jan 2023 Common Stock 83,200 $0.8411 Direct F2
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -2,117 -0.45% $0.000000 470,054 24 Jan 2023 Common Stock 2,117 $0.8411 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.
F2 One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.